# $ rightarrow$ atna ## MEDICARE FORMRiabni ${ }^{ circledR}$ (rituximab-arrx), Rituxan ${ }^{ circledR}$ (rituximab), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs) Medication Precertification Request Page 1 of 5(All fields must be completed and legible for precertification review.)For Medicare Advantage Part B: For other lines of business: Please use commercial form.Note: Riabni and Rituxan are nonpreferred. The preferred biosimilar products are Ruxience and Truxima. For rheumatoid arthritis, all Rituxan and biosimilar products are non-preferred.Would you like to use electronic prior authorization? Consider using Availity, our electronic prior authorization portal. Learn more about Availity from the links in the table below.For phone or fax requests, refer to the table below for routing information. To determine which box to use, refer to the patient's Aetna ID card. State specific special needs and Medicare-Medicaid Plans may be designated on the front of the ID card or in the website URL on the back of the card. If you don't see your specific plan listed, call the number on the back of the member's ID card to confirm routing information.For Aetna Medicare Advantage and Allina Health Aetna Medicare members send request to:Phone: 1-866-503-0857 (TTY: 711)Fax: $ quad 1-844-268-7263$Availity: https:  www.aetna.com health-care-professionals resource-center availity.htmlFor Aetna Medicare Advantage Virginia Dual Eligible Special Needs Plans (HMO D-SNP) send request to:Phone: $ quad 1-855-463-0933$Fax: $ quad 1-833-280-5224$Availity: https:  www.aetnabetterhealth.com virginia-hmosnp providers portalFor Aetna Assure Premier Plus Medicare Advantage New Jersey Dual Eligible Special Needs Plans (HMO D-SNP) send request to:Phone: $ quad 1-844-362-0934$Fax: $ quad 1-833-322-0034$Availity: https:  www.aetnabetterhealth.com new-jersey-hmosnp providers portal.htmlFor Aetna Better Health of Illinois Premier Medicare Medicaid Plan (MMP) send request to:Phone: $ quad 1-866-600-2139$FAX: $ quad 1-855-320-8445$Availity: https:  www.aetnabetterhealth.com illinois providers portalFor Aetna Better Health of Ohio Premier Medicare Medicaid Plan (MMP) send request to:Phone: $ quad 1-855-364-0974$Fax: $ quad 1-855-734-9389$Availity: https:  www.aetnabetterhealth.com ohio providers portalFor Aetna Better Health of Michigan Premier Medicare Medicaid Plan (MMP) send request to:Phone: $ quad 1-855-676-5772$Fax: $ quad 1-844-241-2495$Availity: https:  www.aetnabetterhealth.com michigan providers portal.html
# MEDICARE FORMRiabni® (rituximab-arrx),Rituxan® (rituximab), Ruxience(rituximab-pvvr), Truxima (rituximab-abbs)Medication Precertification RequestPage 2 of 5(All fields must be completed and return both pages for precertification review.)For Medicare Advantage Part B:For other lines of business:Please use commercial form.Note: Riabni and Rituxan are non-preferred. The preferred biosimilarproducts are Ruxience and Truxima.For rheumatoid arthritis, all Rituxan andbiosimilar products are non-preferred.Please indicate: ☐ Start of treatment, start date:                ☐ Continuation of therapy, date of last treatment:                     Precertification Requested By: Phone: Fax:                              A. PATIENT INFORMATIONFirst Name: Last Name: DOB:Address: City: State: ZIP:Home Phone: Work Phone: Cell Phone: E-mail:Current Weight:      lbs or      kgs Height:      inches or      cms Allergies:B. INSURANCE INFORMATIONMember ID #: Does patient have other coverage? ☐ Yes ☐ NoGroup #: If yes, provide ID#: Carrier Name:                              Insured: Insured:                              Insured:                              C. PRESCHIBER INFORMATIONFirst Name: Last Name: (Check one): ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.Address: City: State: ZIP:Phone: Fax: St Lic #: NPI #: DEA #: UPIN:Provider Email: Office Contact Name: Phone:D. DISPENSING PROVIDER ADMINISTRATION INFORMATIONPlace of Administration: Dispensing Provider Pharmacy:☐ Self-administered ☐ Physician's Office ☐ Home ☐ Outpatient Dialysis Center ☐ Physician's Office☐ Outpatient Infusion Center Name: ☐ Retail Pharmacy ☐ Specialty Pharmacy☐ Home Infusion Center Phone: ☐ Mail Order ☐ Other:                              Agency Name: Name:                              ☐ Administration code(s) (CPT): Address: Address:                              City: State: ZIP:                              Phone: Fax: Phone: Fax:                              TIN: PIN: NPI: NPI:                              E. PRODUCT INFORMATIONRequest is for: ☐ Riabni (rituximab-arrx) ☐ Rituxan (rituximab) ☐ Ruxience (rituximab-pvvr) ☐ Truxima (rituximab-abbs)Dose: Directions for Use: HCPCS Code:                              F. DIAGNOSIS INFORMATION - Please indicate primary ICD code and specify any other any other where applicable (*):Primary ICD Code: ☐ Other ICD Code:                              G. CLINICAL INFORMATION - Required clinical information must be completed for ALL precertification requests.For Initiation Requests (clinical documentation required for all requests):Note: Riabni and Rituxan are non-preferred. Ruxience and Truxima are the preferred biosimilars for most indications.For rheumatoid arthritis, all Rituxan and biosimilar products are non-preferred. Inflectra, Renflexis and Simponi Aria are preferred for MA plans.Enbrel, Humira, Idacio, Rinvoq, Tyenne SC and Xeljanz Xeljanz XR are preferred for MAPD plans.☐ Yes ☐ No Has the patient had prior therapy with the requested product within the last 365 days?☐ No Has the patient had a trial and failure of any of the following rituximab biosimilars? (If yes, select all that apply)☐ ☐ Ruxience (rituximab-pvvr) ☐ Truxima (rituximab-abbs)☐ When was the member's trial and failure of the preferred drug?                              ☐ Please describe the nature of the failure of the preferred drug                              ☐ No Has the patient had an adverse reaction to any of the following rituximab biosimilars? (If yes, select all that apply)☐ ☐ Ruxience (rituximab-pvvr) ☐ Truxima (rituximab-abbs)☐ When was the member's adverse reaction to the preferred drug?                              ☐ Please describe the nature of the adverse reaction to the preferred drug                              Please explain if there are any contraindications or other medical reason(s) that the patient cannot use any of the following preferred biosimilar products whenindicated for the patient's diagnosis? (select all that apply)☐ Ruxience (rituximab-pvvr) ☐ Truxima (rituximab-abbs)Continued on next page
# MEDICARE FORMRiabni® (rituximab-arrx),Rituxan® (rituximab), Ruxience(rituximab-pvvr), Truxima (rituximab-abbs)Medication Precertification RequestPage 3 of 5(All fields must be completed and return both pages for precertification review.)For Medicare Advantage Part B:For other lines of business:Please use commercial form.Note: Riabni and Rituxan are non-preferred. The preferred biosimilarproducts are Ruxience and Truxima.For rheumatoid arthritis, all Rituxan andbiosimilar products are non-preferred.Patient First NamePatient Last NamePatient PhonePatient DOBG. CLINICAL INFORMATION (Continued) - Required clinical information must be completed for ALL precertification requests.For Initiation Requests continued (clinical documentation required for all requests):☐ No Has the patient had a trial and failure of any of the following? (If yes, select all that apply)☐ ☐ Inflectra (infliximab-dyyb) ☐ Renflexis (infliximab-abda) ☐ Simponi Aria (golimumab)☐ When was the member's trial and failure of the preferred drug?☐ Please describe the nature of the failure of the preferred drug☐ No Has the patient had an adverse reaction to any of the following? (If yes, select all that apply)☐ ☐ Inflectra (infliximab-dyyb) ☐ Renflexis (infliximab-abda) ☐ Simponi Aria (golimumab)☐ When was the member's adverse reaction to the preferred drug?☐ Please describe the nature of the adverse reaction to the preferred drug☐ No Has the patient had a trial and failure of any of the following? (If yes, select all that apply)☐ ☐ Enbrel (etanercept) ☐ Humira (adalimumab) ☐ Idacio (adalimumab-aacf) ☐ Rinvoq (upadacitinib) ☐ Tyenne SC (tocilizumab-aazg)☐ Xeljanz Xeljanz XR (tofacitinib)☐ When was the member's trial and failure of the preferred drug?☐ Please describe the nature of the failure of the preferred drug☐ No Has the patient had a trial and failure of any of the following? (If yes, select all that apply)☐ ☐ Enbrel (etanercept) ☐ Humira (adalimumab) ☐ Idacio (adalimumab-aacf) ☐ Rinvoq (upadacitinib) ☐ Tyenne SC (tocilizumab-aazg)☐ Xeljanz Xeljanz XR (tofacitinib)☐ When was the member's adverse reaction to the preferred drug?☐ Please describe the nature of the adverse reaction to the preferred drugPlease explain if there are any contraindications or other medical reason(s) that the patient cannot use any of the following preferred products when indicated forthe patient's diagnosis? (select all that apply)☐ Inflectra (infliximab-dyyb) ☐ Renflexis (infliximab-abda) ☐ Simponi Aria (golimumab)Please explain if there are contraindications or any other medical reason(s) that the patient cannot use any of the following preferred products when indicated forthe patient's diagnosis? (select all that apply)☐ Enbrel (etanercept) ☐ Humira (adalimumab) ☐ Idacio (adalimumab-aacf) ☐ Rinvoq (upadacitinib) ☐ Tyenne SC (tocilizumab-aazg)☐ Xeljanz Xeljanz XR (tofacitinib)For All Requests (clinical documentation required for all requests):☐ Yes ☐ No Will Rituxan (rituximab) be used concomitantly with apremilast, tofacitinib, or other biologic DMARDs (e.g., adalimumab, infliximab)?Acute lymphoid leukemia☐ Yes ☐ No Does the patient have a documented diagnosis of Philadelphia chromosome-negative acute lymphoid leukemia (ALL)?☐ Yes ☐ No Is Rituxan (rituximab) being used as induction consolidation therapy?Autoimmune hemolytic anemia☐ Yes ☐ No Does the patient have a documented diagnosis of refractory autoimmune hemolytic anemia?Anti-neutrophil cytoplasmic antibody-associated (ANCA-associated) vasculitidesPlease indicate which of the following applies to the patient: ☐ Wegener granulomatosis ☐ Churg-Strauss syndrome☐ Microscopic polyangiitis ☐ pauci-immune glomerulonephritis☐ Yes ☐ No Will Rituxan (rituximab) be given in conjunction with glucocorticoids?Autoimmune blistering diseases, corticosteroid-refractory☐ Yes ☐ No Does the patient have a documented diagnosis of corticosteroid-refractory autoimmune blistering disease?☐ Please select which applies to the patient: ☐ pemphigus vulgaris ☐ pemphigus folliaceus ☐ bullous pemphigoid ☐ cicatricial pemphigoid☐ epidermolysis bullosa acquisita ☐ paraneoplastic pemphigus ☐ None of the aboveB-cell lymphomasPlease select which applies to the patient: ☐ AIDS-related B-cell lymphoma ☐ Burkitt lymphoma ☐ Diffuse large B-cell lymphoma ☐ Follicular lymphoma☐ Gastric MALT lymphoma ☐ High-grade B-Cell lymphoma ☐ Mantle cell lymphoma☐ Nodal marginal zone lymphoma ☐ Nongastric MALT lymphoma ☐ Primary cutaneous B-cell lymphomas☐ Splenic marginal zone lymphoma ☐ Other:Continued on next page
# MEDICARE FORMRiabni® (rituximab-arrx),Rituxan® (rituximab), Ruxience(rituximab-pvvr), Truxima (rituximab-abbs)Medication Precertification RequestPage 4 of 5(All fields must be completed and return both pages for precertification review.)For Medicare Advantage Part B:For other lines of business:Please use commercial form.Note: Riabni and Rituxan are non-preferred. The preferred biosimilarproducts are Ruxience and Truxima.For rheumatoid arthritis, all Rituxan andbiosimilar products are non-preferred.Patient First NamePatient Last NamePatient PhonePatient DOBG. CLINICAL INFORMATION (Continued) - Required clinical information must be completed for ALL precertification requests.Castleman's disease☐ Yes ☐ No Does the patient have a documented diagnosis of multicentric Castleman's disease (angiofollicular lymph node hyperplasia)?Central nervous system lymphomasPlease select which applies to the patient: ☐ leptomeningeal metastases from lymphoma ☐ primary CNS lymphoma ☐ none of the aboveChronic or small lymphocytic leukemiaPlease select which applies to the patient: ☐ chronic lymphocytic leukemia (CLL) ☐ small lymphocytic leukemia ☐ none of the aboveCryoglobulinemia☐ Yes ☐ No Does the patient have a documented diagnosis of cryoglobulinemia?☐ Yes ☐ No Is there clinical documentation that the treatment with corticosteroids and other immunosuppressive agents was ineffective?Graft versus host disease, chronic☐ Yes ☐ No Is there a documentation that Rituxan (rituximab) being used as last-resort treatment for chronic graft versus host disease (GVHD)?Hairy cell leukemiaPlease select which applies to the patient: ☐ relapsed hairy cell leukemia ☐ refractory hairy cell leukemia ☐ none of the aboveHeart and solid organ transplant☐ Yes ☐ No Is there a documentation that Rituxan (rituximab) is being used for treatment or prevention (desensitization) of highly sensitized patients withantibody mediated rejection in heart transplant recipients and other solid organ transplant recipients?☐ Please select which applies to the patient: ☐ heart transplant recipient ☐ other solid organ transplant recipientImmune checkpoint-inhibitor related encephalitisPlease identify which immune check-point inhibitor caused the encephalitis: ☐ Bavencio (avelumab) ☐ Imfinzi (durvalumab) ☐ Keytruda (pembrolizumab)☐ Opdivo (nivolumab) ☐ Tecentriq (atezolizumab) ☐ Yervoy (ipilimumab)☐ Other:                                                                                                                                                                 Immune or idiopathic thrombocytopenic purpura☐ Yes ☐ No Does the patient have a documented diagnosis of refractory immune or idiopathic thrombocytopenic purpura (ITP)?☐ If refractory immune thrombocytopenic purpura ☐ idiopathic thrombocytopenic purpura (ITP)Kidney transplant, rejection prophylaxis☐ Yes ☐ No Is Rituxan (rituximab) being used as rejection prophylaxis in sensitized kidney transplant recipients with donor specific antibodies?Lymphocyte-predominant Hodgkin's lymphoma☐ Yes ☐ No Does the patient have a documented diagnosis of lymphocyte-predominant Hodgkin's lymphoma?Multiple SclerosisPlease indicate the type of multiple sclerosis the patient has been diagnosed with:☐ Relapsing-remitting MS (RRMS) ☐ Secondary-progressive MS (SPMS) ☐ Primary-progressive MS (PPMS) ☐ Progressive-relapsing MS (PRMS)☐ Yes ☐ No Has the patient discontinued other medications used for treating MS (not including Ampyra)?Myasthenia gravis (MuSk-MG)☐ Yes ☐ No Does the patient have a documented diagnosis of muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG)?☐ Yes ☐ No Has the patient had an unsatisfactory response to initial immunotherapy?Neuromyelitis optica (Devic's disease)☐ Yes ☐ No Does the patient have a documented diagnosis of neuromyelitis optica (Devic's disease)?☐ Yes ☐ No Was the treatment with at least one immunotherapy ineffective?Opsoclonus-myoclonus-ataxia (opsoclonus myoclonus syndrome)☐ Yes ☐ No Does the patient have a documented diagnosis of opsoclonus-myoclonus-ataxia (OMA) associated with neuroblastoma?☐ Yes ☐ No Is the patient refractory to steroids, chemotherapy and intravenous immunoglobulins?☐ Please provide the names and date ranges of medications tried:Medication:
# MEDICARE FORMRiabni® (rituximab-arrx),Rituxan® (rituximab), Ruxience(rituximab-pvvr), Truxima (rituximab-abbs)Medication Precertification RequestFor Medicare Advantage Part B:For other lines of business:Please use commercial form.Note: Riabni and Rituxan are non-preferred. The preferred biosimilarproducts are Ruxience and Truxima.For rheumatoid arthritis, all Rituxan andbiosimilar products are non-preferred.Page 5 of 5(All fields must be completed and return both pages for precertification review.)Patient First Name Patient Last Name Patient Phone Patient DOBG. CLINICAL INFORMATION (Continued) - Required clinical information must be completed for ALL precertification requests.Rheumatoid ArthritisPlease indicate the severity of the patient's rheumatoid arthritis: ☐ Mild ☐ Moderate ☐ Severe☐ Yes ☐ No Is there evidence that the disease is active?☐ Yes ☐ No Will Rituxan (rituximab) be used in combination with methotrexate?↔☐ Yes ☐ No Was treatment with methotrexate ineffective, not tolerated or contraindicated?↔☐ Please select: ☐ ineffective ☐ not tolerated ☐ contraindicated☐ Yes ☐ No Was treatment with another conventional DMARD ineffective?↔☐ Please select: ☐ azathioprine ☐ cyclosporine ☐ hydroxychloroquine ☐ leflunomide ☐ sulfasalazineSjögren syndrome☐ Yes ☐ No Does the patient have a documented diagnosis of Sjögren's syndrome?☐ Yes ☐ No Was treatment with corticosteroids and other immunosuppressive agents ineffective?↔☐ Please provide the names and dates of the corticosteroids and other immunosuppressive agents used:Medication: Dates:   Medication: Dates:   Thrombotic thrombocytopenic purpura☐ Yes ☐ No Does the patient have a documented diagnosis of refractory thrombotic thrombocytopenic purpura (TTP)?Waldenstrom's macroglobulinemia☐ Yes ☐ No Does the patient have a documented diagnosis of Waldenström macroglobulinemia?For Continuation Requests:☐ Yes ☐ No Is this continuation request a result of the patient receiving samples of Rituxan (rituximab)?Please indicate the length of time on Rituxan (rituximab):